Lauren P. Cobb, M.D.
Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery
Present Title & Affiliation
Primary Appointment
Executive Director of Surgery, University of Texas MD Anderson Cancer Network, The University of Texas MD Anderson Cancer Center, Houston, Texas
Associate Professor, Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Associate Professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Tx
Education & Training
Degree-Granting Education
| 2010 | Baylor College of Medicine, Houston, Texas, US, MD |
| 2004 | Duke University, Durham, North Carolina, US, BA in Public Policy |
Postgraduate Training
| 2014-2017 | Clinical Fellowship, Gynecologic Oncology, Duke University Medical Center, Durham, North Carolina |
| 2010-2014 | Clinical Residency, Obstetrics & Gynecology, Johns Hopkins University, Baltimore, Maryland |
Licenses & Certifications
| 2019 | American Board of Obstetrics and Gynecology, Gynecologic Oncology |
| 2018 | American Board of Obstetrics and Gynecology |
| 2017 | DEA |
| 2017 | Texas Medical Board |
Experience & Service
Faculty Academic Appointments
Assistant Professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2017 - 2023
Fellow, Gynecologic Oncology, Duke University Medical Center, Durham, NC, 2014 - 2017
Resident, Johns Hopkins University, Baltimore, MD, 2010 - 2014
Other Professional Positions
Director, Cancer Network for Gynecologic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Tx, 2024 - Present
Billing and Coding Liaison, The University of Texas MD Anderson Cancer Center, Houston, Tx, 2021 - Present
Extramural Institutional Committee Activities
Member, Goals of Care Committee Leadership Team, The University of Texas MD Anderson Cancer Center, 2024 - Present
Alternate, OR Advisory Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Medical Practice Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Gynecologic Oncology Fellowship Education Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Gynecologic Oncology Fellowship Program Evaluation Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, MD Anderson Northwest Houston Surgical Center OR Advisory Committee, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, Gynecologic Oncology Fellowship Clinical Competency Committee, The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Scientific Review Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, MD Anderson Northwest Houston Hospital APP Taskforce, The University of Texas MD Anderson Cancer Center, 2022 - 2023
Wellness officer for the Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery Wellness Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Alternate, Credentialing Committee of the Medical Staff, The University of Texas MD Anderson Cancer Center, 2020 - 2023
Member, Faculty Senate, The University of Texas MD Anderson Cancer Center, 2020 - 2023
Member, Gynecologic Oncology Fellowship Admissions Subcommittee, The University of Texas MD Anderson Cancer Center, 2020 - Present
Member, The Department of Gynecologic Oncology Surgery Working Group, The University of Texas MD Anderson Cancer Center, 2019 - Present
Member, Perioperative Services Value Analysis Team, The University of Texas MD Anderson Cancer Center, 2019 - 2024
Member, Pharmacy and Therapeutics Committee, The University of Texas MD Anderson Cancer Center, 2018 - 2024
Member, The Department of Gynecologic Oncology Ovarian Cancer Working Group, The University of Texas MD Anderson Cancer Center, 2017 - Present
Honors & Awards
| 2023 - 2024 | Society of Gynecologic Oncology Bridges Research Initiative Scholar |
| 2023 | Top Performer Award, Top 10%, MD Anderson Cancer Center |
| 2020 | Top Performer Award, Top 10%, MD Anderson Cancer Center |
| 2019 - 2022 | GOG Foundation New Investigator Award, GOG Foundation |
| 2019 | Top Performer Award, Top 1%, MD Anderson Cancer Center |
| 2018 | Top Performer Award, Top 10%, MD Anderson Cancer Center |
| 2017 | Charles B. Hammond Research Day Fellow Prize, Duke University Medical Center |
| 2016 | Outstanding Fellow Student Teaching Award, Duke University Medical Center |
| 2010 | Glasgow-Rubin Certificate of Commendation for Academic Achievement, American Medical Women's Association |
| 2010 | Houston Gynecological & Obstetrical Society Award, Houston Gynecological & Obstetrical Society |
| 2010 | Society for Gynecologic Investigation President's Presenter Award, Society for Gynecologic Investigation |
| 2009 | Alpha Omega Alpha Honor Society, Alpha Omega Honor Society |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2024. "Updates in the Management of Low-Grade Serous Ovarian Cancer". Conference. MD Anderson GYN Cancer Network Retreat, Virtual. Houston, Tx, US.
- 2022. Management of Recurrent Platinum Sensitive Ovarian Cancer. Conference. Management of Recurrent Platinum Sensitive Ovarian Cancer. Houston, TX, US.
- 2020. "Diagnosis and Management of Cervical Cancer and Pre-Invasive Disease". Invited. Brazos Valley Nurse Practitioner Association. College Station, Texas, US.
- 2019. "Alternative Medicine: Common Myths and Misperceptions". Conference. "Alternative Medicine: Common Myths and Misperceptions". Houston, TX, US.
- 2019. "Screening, Diagnosis, and Management of Cervical Cancer". Invited. North Harris Montgomery Advanced Practice Nurse Society Dinner. The Woodlands, Texas, US.
Regional Presentations
- 2020. "Diagnosis and Management of Cervical Cancer and Pre-Invasive Disease". Conference. "Diagnosis and Management of Cervical Cancer and Pre-Invasive Disease". College Station, TX, US.
- 2019. "Screening, diagnosis, and management of cervical cancer". Conference. "Screening, diagnosis, and management of cervical cancer". The Woodlands, TX, US.
National Presentations
- 2025. Ovarian Low and High-Grade Serous Carcinoma as a Synchronous or Metachronous Phenomenon: A Cohort of 30 Cases. Poster. Society of Gynecologic Oncology Annual Meeting on Women's Cancer. Seattle, WA, US.
- 2024. "Paradigm Changes and New Opportunities to Treat Low Grade Serous Ovarian Cancer". Invited. Great Debates and Updates in Women's Oncology. Nashville, TN, US.
- 2024. "Borrowing From Breast Cancer: Endocrine Combinations in Endometrial Cancer". Invited. American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL, US.
- 2024. "Updates in the Management of Low-Grade Serous Ovarian Cancer". Conference. Felix Rutledge Society Meeting, Gynecologic Oncology and Reproductive Medicine. Ft. Lauderdale, FL, US.
- 2024. Prognostic Implications of Minimal Residual Disease Detection by Second Look Laparoscopy and Circulating Tumor DNA in Patients with Ovarian Caner after Frontline Therapy. Conference. Society of Gynecologic Oncology Annual Meeting. San Diego, CA, US.
- 2024. CDK4/6 Inhibitors Potently Inhibit Cell Viability in Pre-Clinical Models of Adult Type Ovarian Granulose Cell Tumors. Poster. Society of Gynecologic Oncology Annual Meeting on Women's Cancer. San Diego, CA, US.
- 2024. "Adjuvant Hormone Directed Therapy in GYN Cancer". Invited. Society of Gynecologic Oncology Winter Meeting. Olympic Valley, CA, US.
- 2023. Clinical and genomic landscape of RAS mutation in gynecologic cancers. Poster. Clinical and genomic landscape of RAS mutation in gynecologic cancers. Chicago, IL, US.
- 2023. Characterization of RAS mutation in gynecologic cancers and response to targeted therapy. Poster. Characterization of RAS mutation in gynecologic cancers and response to targeted therapy. Tampa, FL, US.
- 2023. NOW: Neoadjuvant Olaparib Window Trial in Patients with Newly Diagnosed BRCA Mutant Ovarian Cancer. Conference. NOW: Neoadjuvant Olaparib Window Trial in Patients with Newly Diagnosed BRCA Mutant Ovarian Cancer. Tampa, FL, US.
- 2022. A Pilot Phase II Study of Neoadjuvant Fulvestrant plus Abemaciclib in Women with Advanced Low Grade Serous Carcinoma. Poster. A Pilot Phase II Study of Neoadjuvant Fulvestrant plus Abemaciclib in Women with Advanced Low Grade Serous Carcinoma. Chicago, IL, US.
- 2022. "The Clinical Course of Women Who Undergo Contemporary Management of Stage II-IV Low Grade Serous Carcinoma. Poster. "The Clinical Course of Women Who Undergo Contemporary Management of Stage II-IV Low Grade Serous Carcinoma. Phoenix, AZ, US.
- 2022. "PANDA: A prospective study of the prevalence of anal dysplasia among women with high-grade cervical, vaginal, and vulvar dysplasia or cancer". Conference. "PANDA: A prospective study of the prevalence of anal dysplasia among women with high-grade cervical, vaginal, and vulvar dysplasia or cancer". Phoenix, AZ, US.
- 2021. ENPAC: phase II trial with safety lead of enzalutamide in combination with paclitaxel and carboplatin for advanced or recurrent endometrioid endometrial adenocarcinoma. Conference. ENPAC: phase II trial with safety lead of enzalutamide in combination with paclitaxel and carboplatin for advanced or recurrent endometrioid endometrial adenocarcinoma. Virtual Meeting, US.
- 2019. Bevacizumab beyond progression: Impact of subsequent bevacizumab retreatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression. Poster. Bevacizumab beyond progression: Impact of subsequent bevacizumab retreatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression. Chicago, IL, US.
- 2019. Correlation of surgeon radiology assessment with laparoscopic scoring in patients with advanced stage ovarian cancer. Poster. Correlation of surgeon radiology assessment with laparoscopic scoring in patients with advanced stage ovarian cancer. Chicago, IL, US.
- 2019. "Current and Evolving Treatments for Gynecologic Malignancies. Conference. C.A.R.E. Women's Cancer Conference. Cocoa Beach, FL, US.
- 2019. "Maintenance Therapy for Long Term Survival. Conference. C.A.R.E. Women's Cancer Conference. Cocoa Beach, FL, US.
- 2019. The role of neoadjuvant chemotherapy in the management of low grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. Poster. The role of neoadjuvant chemotherapy in the management of low grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. Honolulu, HI, US.
- 2019. The use of a laparoscopic algorithm to triage the timing of cytoreductive surgery in patients with low grade serous ovarian and peritoneal cancer. Poster. The use of a laparoscopic algorithm to triage the timing of cytoreductive surgery in patients with low grade serous ovarian and peritoneal cancer. Honolulu, HI, US.
- 2018. Targeting the TIE2 pathway with novel small molecule VE-PTP inhibitor, AKB-9785, in high grade serous ovarian cancer. Conference. Targeting the TIE2 pathway with novel small molecule VE-PTP inhibitor, AKB-9785, in high grade serous ovarian cancer. New Orleans, LA, US.
- 2018. Obesity is associated with altered angiogenic gene expression in endometrioid endometrial cancer. Poster. Obesity is associated with altered angiogenic gene expression in endometrioid endometrial cancer. New Orleans, LA, US.
- 2017. Differential expression of immune related genes in high grade ovarian serous carcinoma (HGSC): A platform for drug and biomarker discovery. Poster. Differential expression of immune related genes in high grade ovarian serous carcinoma (HGSC): A platform for drug and biomarker discovery. National Harbor, MD, US.
- 2016. CRISPR-CAS9 negative selection screen identifies genes that sensitize high grade serous ovarian cancer cell lines to carboplatin, paclitaxel, and olaparib. Poster. CRISPR-CAS9 negative selection screen identifies genes that sensitize high grade serous ovarian cancer cell lines to carboplatin, paclitaxel, and olaparib. San Diego, CA, US.
- 2015. Evaluation of ERRα expression and association with survival in advanced ovarian cancer. Poster. Evaluation of ERRα expression and association with survival in advanced ovarian cancer. Chicago, IL, US.
- 2014. Evaluation of ERRα expression and association with survival in advanced ovarian cancer. Conference. Evaluation of ERRα expression and association with survival in advanced ovarian cancer. Chapel Hill, NC, US.
- 2014. Trends in patient care after discontinuation of daily progress checklists after transition to electronic patient documentation: evaluation of prophylactic compliance and surgical outcomes among gynecologic oncology patients. Poster. Trends in patient care after discontinuation of daily progress checklists after transition to electronic patient documentation: evaluation of prophylactic compliance and surgical outcomes among gynecologic oncology patients. Tampa, FL, US.
- 2013. Effector T cells and regulatory T cells at the tissue site of squamous cell cervical cancer in patients with inoperable disease can be used to predict response to conventional treatment modalities. Conference. Effector T cells and regulatory T cells at the tissue site of squamous cell cervical cancer in patients with inoperable disease can be used to predict response to conventional treatment modalities. Seattle, WA, US.
- 2012. Introduction of checklists at daily progress notes improves patient care among the gynecologic oncology service. Poster. Introduction of checklists at daily progress notes improves patient care among the gynecologic oncology service. Austin, TX, US.
- 2011. A reduction in Hepatic MicroRNA (MIR675) is associated with an increase in H19 expression in a transgenerational model of IUGR. Poster. A reduction in Hepatic MicroRNA (MIR675) is associated with an increase in H19 expression in a transgenerational model of IUGR. Portland, OR, US.
- 2011. Introduction of checklists at daily progress notes improves patient care among the gynecologic oncology service. Conference. Introduction of checklists at daily progress notes improves patient care among the gynecologic oncology service. Baltimore, MD, US.
- 2011. Maternal tobacco use is associated with increased markers of oxidative stress in the placenta. Poster. Maternal tobacco use is associated with increased markers of oxidative stress in the placenta. San Francisco, CA, US.
- 2011. Maternal tobacco use alters genome wide DNA methylation and gene expression in placental tissue. Poster. Maternal tobacco use alters genome wide DNA methylation and gene expression in placental tissue. San Francisco, CA, US.
- 2011. Maternal tobacco use and maternal obesity alter mitochondrial DNA in placental tissue. Poster. Maternal tobacco use and maternal obesity alter mitochondrial DNA in placental tissue. San Francisco, CA, US.
- 2010. Alterations in expression of the growth-related imprinted gene H19 in a transgenerational model of IUGR. Conference. Alterations in expression of the growth-related imprinted gene H19 in a transgenerational model of IUGR. Orlando, FL, US.
- 2010. Essential nutrient supplementation preventing adult metabolic disease is associated with altered expression of mitochondrial regulators in a transgenerational model of IUGR. Conference. Essential nutrient supplementation preventing adult metabolic disease is associated with altered expression of mitochondrial regulators in a transgenerational model of IUGR. Orlando, FL, US.
International Presentations
- 2024. Minimal Residual Disease as a Prognostic Marker and Opportunity for Intervention in Advanced Ovarian Cancer. Poster. International Gynecologic Cancer Society (IGCS) Annual Meeting. Dublin, IE.
- 2018. "Low Grade Serous Carcinoma of the Ovary: Contemporary Management and Emerging Concepts". Invited. MD Anderson Felix Rutledge Society Meeting, Gynecologic Oncology and Reproductive Medicine. Barcelona, ES.
Grant & Contract Support
| Date: | 2016 - 2016 |
| Title: | The Charles B. Hammond Research Fund |
| Funding Source: | Duke University Medical Center |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Grisham, RN, Monk, BJ, Van Nieuwenhuysen, E, Moore, K, Fabbro, M, O'Malley, DM, Oaknin, A, Thaker, PH, Oza, A, Colombo, N, Gershenson, DM, Aghajanian, C, Choi, CH, Lee, YC, Mirza, MR, Coleman, R, Cobb, LP, Harter, P, Lustgarten, S, Youssoufian, H, Banerjee, S. GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301. International Journal of Gynecological Cancer 35(11), 2025. e-Pub 2025. PMID: 39375168.
- Brodsky, AL, Welte, T, Vuttaradhi, VK, Yang, X, Tahan, E, Khlebus, E, Celestino, J, Powell, RT, Stephan, C, Nguyen, N, Geng, Y, Li, J, Takamatsu, S, Calzoncinth, K, Cobb, LP, Gershenson, DM, Lawson, BC, Hillman, RT. Efficacy of cyclin-dependent kinase 4/6 inhibitors in preclinical adult-type ovarian granulosa cell tumor models. Gynecologic oncology 201:152-159, 2025. e-Pub 2025. PMID: 40886461.
- Brodsky, AL, Sun, CC, Cobb, LP, Westin, SN, Malpica, A, Gershenson, DM. Ovarian mixed low- and high-grade serous carcinoma as a synchronous or metachronous phenomenon. Gynecologic oncology 200:130-136, 2025. e-Pub 2025. PMID: 40749518.
- Asare, A, Previs, RA, Spinosa, D, Fellman, B, Scott, AL, Mulder, I, Mahmoud, M, Enbaya, A, Siedel, J, Cobb, LP, Soliman, PT, Sood, AK, Coleman, R, Secord, AA, Westin, SN. Bevacizumab beyond progression. Gynecologic oncology 194:112-118, 2025. e-Pub 2025. PMID: 39987772.
- Son, J, Zhang, Y, Lin, Y, Mirallas, O, Ballesteros, PA, Nardo, M, Clark, N, Hillman, RT, Campbell, E, Holla, V, Johnson, A, Biter, A, Yuan, Y, Cobb, LP, Gershenson, DM, Jazaeri, AA, Lu, KH, Soliman, PT, Westin, SN, Euscher, ED, Lawson, BC, Yang, RK, Meric-Bernstam, F, Hong, DS. Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers. Clinical Cancer Research 30(14):2986-2995, 2024. e-Pub 2024. PMID: 38687597.
- Batman, S, Messick, C, Milbourne, A, Guo, M, Munsell, M, Fokom Domgue, J, Salcedo, MP, Deshmukh, AA, Dahlstrom, KR, Ogburn, M, Price, A, Fleming, N, Taylor, JS, Shafer, A, Cobb, LP, Sigel, K, Sturgis, EM, Chiao, EY, Schmeler, KM. A Cross-Sectional Study of the Prevalence of Anal Dysplasia among Women with High-Grade Cervical, Vaginal, and Vulvar Dysplasia or Cancer. Cancer Epidemiology Biomarkers and Prevention 31(12):2185-2191, 2022. e-Pub 2022. PMID: 36126275.
- Gershenson, DM, Cobb, LP, Westin, SN, Zhang, Y, Jazaeri, AA, Malpica, A, Sun, CC. Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC). Gynecologic oncology 167(2):139-145, 2022. e-Pub 2022. PMID: 36137845.
- Gershenson DM, Cobb LP, Westin SN, Zhang Y, Jazaeri A, Malpica A, Sun CC. Contemporary Primary Treatment of Women with Stage II-IV Low-Grade Serous Ovarian/Peritoneal Cancer (LGSOC): Determinants of Relapse and Disease-Free Survival. Gynecologic Oncology 167(2):139-145, 2022. e-Pub 2022.
- Gershenson DM, Sun CC, Westin SN, Eyada M, Cobb LP, Nathan LC, Sood AK, Malpica A, Hillman RT, Wong KK. The genomic landscape of low-grade serous ovarian/peritoneal carcinoma and its impact on clinical outcomes. Gynecol Oncol 165(3):560-567, 2022. e-Pub 2022. PMID: 35606067.
- Cobb LP, Siamakpour-Reihani S, Zhang D, Qin X, Owzar K, Zhou C, Conrads TP, Maxwell GL, Darcy KM, Bateman N, Litzi T, Bae-Jump V, Secord AA. Obesity and altered angiogenic-related gene expression in endometrial cancer. Gynecol Oncol 163(2):320-326, 2021. e-Pub 2021. PMID: 34538531.
- Fleming ND, Westin SN, Rauh-Hain JA, Soliman PT, Fellman BM, Coleman RL, Meyer LA, Shafer A, Cobb LP, Jazaeri A, Lu KH, Sood AK. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Gynecol Oncol 162(1):65-71, 2021. e-Pub 2021. PMID: 33838925.
- Fleming, N, Westin, SN, Meyer, LA, Shafer, A, Rauh-Hain, JA, Onstad Grinsfelder, MA, Cobb, LP, Bevers, MW, Fellman, B, Burzawa, JK, Bhosale, PR, Zand, B, Jazaeri, AA, Levenback, CF, Coleman, R, Soliman, PT, Sood, AK. Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. International Journal of Gynecological Cancer 31(1):92-97, 2021. e-Pub 2021. PMID: 33154095.
- Fleming ND, Westin SN, Meyer LA, Shafer A, Rauh-Hain JA, Onstad M, Cobb L, Bevers M, Fellman BM, Burzawa J, Bhosale P, Zand B, Jazaeri A, Levenback C, Coleman RL, Soliman PT, Sood AK. Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. Int J Gynecol Cancer 31(1):92-97, 2021. e-Pub 2021.
- Gershenson DM, Cobb LP, Sun CC. Endocrine therapy in the management of low-grade serous ovarian/peritoneal carcinoma: Mounting evidence for the relative efficacy of tamoxifen and aromatase inhibitors. Gynecol Oncol 159(3):601-603, 2020. e-Pub 2020. PMID: 33019983.
- Cobb LP, Sun CC, Iyer R, Nick AM, Fleming ND, Westin SN, Sood AK, Wong KK, Silva EG, Gershenson DM. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance. Gynecol Oncol 158(3):653-658, 2020. e-Pub 2020. PMID: 32709538.
- Slomovitz B, Gourley C, Carey MS, Malpica A, Shih IM, Huntsman D, Fader AN, Grisham RN, Schlumbrecht M, Sun CC, Ludemann J, Cooney GA, Coleman R, Sood AK, Mahdi H, Wong KK, Covens A, O'Malley DM, Lecuru F, Cobb LP, Caputo TA, May T, Huang M, Siemon J, Fernández ML, Ray-Coquard I, Gershenson DM. Low-grade serous ovarian cancer: State of the Science. Gynecol Oncol 156(3):715-725, 2020. e-Pub 2020. PMID: 31969252.
- Siamakpour-Reihani S, Cobb LP, Jiang C, Zhang D, Previs RA, Owzar K, Nixon AB, Alvarez Secord A. Differential expression of immune related genes in high-grade ovarian serous carcinoma. Gynecol Oncol 156(3):662-668, 2020. e-Pub 2020. PMID: 31918995.
- Schwartz AR, Lim S, Broadwater G, Cobb L, Valea F, Marosky Thacker J, Habib A, Havrilesky L. Reduction in opioid use and postoperative pain scores after elective laparotomy with implementation of enhanced recovery after surgery protocol on a gynecologic oncology service. Int J Gynecol Cancer 29(5):935-943, 2019. e-Pub 2019. PMID: 31155518.
- Moulton LJ, Michener CM, Levinson K, Cobb L, Tseng J, Jernigan A. Compliance with research standards within gynecologic oncology fellowship: A Gynecologic Oncology Fellowship Research Network (GOFRN) study. Gynecol Oncol 146(3):647-652, 2017. e-Pub 2017. PMID: 28698010.
- Wu ES, Oduyebo T, Cobb LP, Cholakian D, Kong X, Fader AN, Levinson KL, Tanner EJ, Stone RL, Piotrowski A, Grossman S, Roche KL. Lymphopenia and its association with survival in patients with locally advanced cervical cancer. Gynecol Oncol 140(1):76-82, 2016. e-Pub 2016. PMID: 26571200.
- Diaz-Montes TP, Cobb L, Ibeanu OA, Njoku P, Gerardi MA. Introduction of checklists at daily progress notes improves patient care among the gynecological oncology service. J Patient Saf 8(4):189-93, 2012. e-Pub 2012. PMID: 23007241.
- Suter M, Ma J, Harris A, Patterson L, Brown KA, Shope C, Showalter L, Abramovici A, Aagaard-Tillery KM. Maternal tobacco use modestly alters correlated epigenome-wide placental DNA methylation and gene expression. Epigenetics 6(11):1284-94, 2011. e-Pub 2011. PMID: 21937876.
- Sbrana E, Suter MA, Abramovici AR, Hawkins HK, Moss JE, Patterson L, Shope C, Aagaard-Tillery K. Maternal tobacco use is associated with increased markers of oxidative stress in the placenta. Am J Obstet Gynecol 205(3):246.e1-7, 2011. e-Pub 2011. PMID: 21803321.
- Durgan DJ, Trexler NA, Egbejimi O, McElfresh TA, Suk HY, Patterson LE, Shaw CA, Hardin PE, Bray MS, Chandler MP, Chow CW, Young ME. The circadian clock within the cardiomyocyte is essential for responsiveness of the heart to fatty acids. J Biol Chem 281(34):24254-69, 2006. e-Pub 2006. PMID: 16798731.
Invited Articles
- Cobb LP, Gershenson D. Novel therapeutics in low-grade serous ovarian cancer. Int J Gynecol Cancer 33(3):377-384, 2023. e-Pub 2023. PMID: 36878564.
- Cobb LP, Gershenson DM. Treatment of Rare Epithelial Ovarian Tumors. Hematol Oncol Clin North Am 32(6):1011 - 1024, 2018. e-Pub 2018. PMID: 30390757.
- Cobb L, Secord A. Association between Obesity and Clinical Outcomes in Gynecologic Cancer. Current Obstetrics and Gynecology Reports 4((4)):1-9, 2015. e-Pub 2015.
- Cobb LP, Gaillard S, Wang Y, IeM S, Secord AA. Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms. Gynecol Oncol Res Pract 2:1, 2015. e-Pub 2015. PMID: 27231561.
Review Articles
- Podder, V, Grisham, RN, Coleman, R, Cobb, LP, Monk, BJ, Herzog, TJ, Gershenson, DM, Slomovitz, BM. Repurposing Food and Drug Administration-approved cancer therapies. International Journal of Gynecological Cancer 35(12), 2025. e-Pub 2025. PMID: 40480868.
- Chelariu-Raicu A, Cobb LP, Gershenson DM. Fertility preservation in rare ovarian tumors. Int J Gynecol Cancer 31(3):432-441, 2021. e-Pub 2021. PMID: 33649010.
Book Chapters
- Cobb, LP, Gershenson, DM. Borderline Ovarian Tumours and Low-Grade Serous Carcinoma, 95-106, 2026.
- Roni Nitecki CA, Cobb LP, J Alejandro Rauh-Hain J, Jazaeri A. Ovarian Cancer. In: MD Anderson Manual of Medical Oncology, Fourth edition. McGraw Hill, 2022.
- Cobb LP, Giuntoli RL. Gestational Trophoblastic Disease. In: Johns Hopkins Manual of Gynecology and Obstetrics. 5. LWW, 2015.
- Cobb LP, Giuntoli RL. Palliative Care. In: Johns Hopkins Manual of Gynecology and Obstetrics. 5. LLW, 2015.
Patient Reviews
CV information above last modified September 09, 2026